Abortion pill mifepristone is banned or restricted in some states despite Supreme Court ruling

Abortion pill mifepristone is banned or restricted in some states despite Supreme Court ruling


In this photo illustration, packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023 in Rockville, Maryland.

Anna Moneymaker | Getty Images

The abortion pill mifepristone is either banned or restricted to varying degrees in 27 states despite a Supreme Court decision that — for now — maintains Food and Drug Administration regulations allowing easy access to the medication.

The Supreme Court, acting on an emergency basis, last week blocked lower federal court orders that had imposed severe restrictions on mifepristone even in some states where abortion remains legal.

The ruling stemmed from a lawsuit against the FDA by a coalition of doctors who oppose abortion. That group wants to force the agency to pull mifepristone from the market entirely. The Biden administration is opposing that effort.

The U.S. 5th Circuit Court of Appeals is now scheduled to hear oral arguments in the case on May 17.

The side that loses at the appeals courts is certain to ask the Supreme Court to take the case to make a final determination on the legality of the FDA rules.

The FDA rules upheld by the Supreme Court on Friday for several years have allowed women to obtain a mifepristone prescription through a telehealth appointment and to receive the medication by mail.

Patients previously were required by FDA to obtain mifepristone in-person from a health-care provider or take the medication under their supervision.

While the Supreme Court’s decision at least temporarily maintains access to mifepristone in states that support broad access to abortion, it will have less or no impact in conservative states that banned the procedure since last summer, when the high court overturned the half-century-old federal constitutional right to abortion.

CNBC Health & Science

Read CNBC’s latest global health coverage:

Mifepristone will remain largely unavailable in 13 states that have completely banned abortion.

Those states are Alabama, Arkansas, Idaho, Kentucky, Louisiana, Mississippi, Missouri, North Dakota, Oklahoma, South Dakota, Tennessee, Texas and West Virginia, according to the Guttmacher Institute, a nonprofit group that supports abortion access.

All of those states have exceptions that allow abortion when the woman’s life is in danger.

And Idaho, West Virginia and North Dakota have exceptions for pregnancies that result from rape and incest, although in North Dakota that exception applies only through the sixth week of pregnancy.

Fourteen other states have restrictions on mifepristone that go beyond the FDA regulations temporarily upheld by the Supreme Court.

Those states require women to obtain the pill from a doctor.

Those states are: Alaska, Arizona, Florida, Georgia, Indiana, Iowa, Michigan, Nebraska, Nevada, North Carolina, Ohio, Pennsylvania, South Carolina and Utah.

Florida, Georgia and Ohio ban abortion after six weeks before many women know they are pregnant.

Mifepristone is FDA-approved to terminate an early pregnancy up to the 10th week of pregnancy.

There are pending federal lawsuits in North Carolina and West Virginia that seek to overturn those states’ mifepristone restrictions.



Source

OpenAI acquires health-care technology startup Torch
Health

OpenAI acquires health-care technology startup Torch

OpenAI has acquired the health-care technology startup Torch, the company announced on Monday. Torch was building a “unified medical memory” for artificial intelligence that aimed to bring a patient’s health data, which is typically siloed and stored across a number of different vendors and formats, into one place. Torch’s employees will join OpenAI as part […]

Read More
Thanks for your support, here’s how to connect with us
Health

Thanks for your support, here’s how to connect with us

When Becky Quick announced the CNBC Cures initiative, our effort to raise awareness for rare diseases and improve the lives of the 30 million people living with them, we knew the response would be big. We didn’t know it would be this big. The response has been amazing, overwhelming and humbling. Thank you for your interest — […]

Read More
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Health

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]

Read More